Letrozole

Letrozole is a third generation inhibitor of aromatase with IC50 of 0.07-20 nM.

Price Stock Quantity  
In DMSO USD 480 In stock
USD 97 In stock
USD 170 In stock
USD 470 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Letrozole Chemical Structure

Letrozole Chemical Structure
Molecular Weight: 285.3

Validation & Quality Control

Customer Reviews(1)

Quality Control & MSDS

Related Compound Libraries

Product Information

  • Compare Aromatase Inhibitors
    Compare Aromatase Products
  • Research Area

Product Description

Biological Activity

Description Letrozole is a third generation inhibitor of aromatase with IC50 of 0.07-20 nM.
Targets Aromatase
IC50 0.07 nM-20 nM [1]
In vitro Letrozole potently inhibits aromatase derived from a variety of different sources including human placental microsomes, particulate fractions of human breast cancer, rat ovarian microsomes, MCF-7 cells transfected with aromatase (MCF-7Ca), JEG-3 human choriocarcinoma cells , CHO cells, hamster ovarian tissue, and particulate fractions of human breast cancer with IC50 of 11, 2, 7, 0.07, 0.07, 1.4, 20 and 0.8 nM. In the non-cellular systems, the IC50 of letrozole is calculated to be 1-13 nM. [1] Letrozole maximally inhibits estradiol production in vitro in LH-stimulated hamster ovarian tissue at 0.1 μM with an IC50 of 0.02 μM and does not significantly affect progesterone production up to 350 μM. In ACTH-stimulated rat adrenal tissue in vitro, aldosterone production is inhibited by with an IC50 of 210 μM. [2] Letrozole inhibits growth of the MCF-7 epithelial breast cancer cells in a dose-dependent way with IC50 of 1 nM. Inhibition can be observesed even at the very low concentrations tested (0.1 nM). Treatment of normal MCF-12A epithelial cells with letrozole did not affect their growth even when high letrozole concentrations (100 nM) or prolonged culture times. Letrozole (10 nM) significantly suppressed the stimulatory effects of 4-androstene-3,17-dione (100 nM) or testosterone (100 nM) on MCF-7 cell proliferation. Concurrent administration of 17-β-estradiol with letrozole (10 nM) decreased the stimulatory effect of the enzymatic activity of MMP-2 and - 9 released by estradiol. [3]
In vivo Letrozole inhibits aromatase in vivo with ED50 of 1-3 μg/kg p.o.. [2] Letrozole displays anti-endocrine effects. Letrozole inhibits androstenedione-induced uterine hypertrophy in immature rats with ED50 of 1-3 μg/kg. In the adult female rat, Letrozole (0.3-1 mg/kg daily p.o., 14 days) completely interrupts ovarian cyclicity and reduces uterine weight and serum estradiol (E2) concentrations to a similar extent to that seen after ovariectomy. [1] Letrozole induces dose-dependent regression of estrogen-dependent, 9,10-dimethylbenz-a-anthracene (DMBA)-induced mammary tumors in adult female rats. The ED50 for Letrozole is determined to be 10 - 30 µg/kg/day, with complete inhibition at a daily dose of 10 µg/day. [4] Letrozole produces dose-dependent inhibition of tumor growth of MCF-7 cells transfected with human aromatase gene (MCF-7Ca) implanted athymic nude mice, with complete inhibition at 20 mg/kg per day p.o.. [5]
Features

Protocol(Only for Reference)

Kinase Assay: [6]

Human placental aromatase activity The assay is performed in a total volume of 1 mL at 37 ℃. Unless otherwise noted, the incubation mixture contains 11 nM [4- 14C] androstene-3, 17-dione ([4- 14C]A), 24 mM NADPH (tetrasodium salt Type III), the appropriate concentrations of the desired inhibitor, and 120 μg of microsomal protein. The (4- 14C)A is added as a solution in 1.7% ethanol in 0.05 M potassium phosphate buffer (pH 7.4), so that the final concentration of ethanol does not exceed 0.02% (v/v). The reaction is started by the addition of enzyme and stopped after 20 min by the addition of 7 vol of ethyl acetate. The mixture is agitated on a vortex mixer and centrifuged at 600 g for 5 min. The aqueous phase is re-extracted with 7 vol of ethyl acetate, and the combined extracts are evaporated to dryness using an Evapo-Mix. Over 99% of the radio- active of [4- 14C] added is recovered using this extraction system. The residue obtained is dissolved in 150 μL acetone, and 100 μL aliquots are chromatographed for 65 min on thin-layer plates precoated with silica gel 60 using ethyl: acetate: isooctane (140:60, v/v; system A) or toluene: chloroform: methanol (70:140:20; system B). The radioactive zones of the plate are located with a Berthold LB 2760 thin-layer scanner. The radioactive estradiol (E2) and estrone (E1) neaks are identified by comparison with authentic standards. The corresponding bonding band of silica gel is transferred to vials containing 10 mL of scintillation fluid, and counted with a 6880 Liquid Scintillation system.

Cell Assay: [3]

Cell lines Human breast cancer cells MCF-7
Concentrations ~100 nM
Incubation Time 1 days
Method Cells are seeded in duplicate at 5,000 to 10,000 cells per well in 24-well plates. The day after plating, different concentrations of Letrozole are added. At the end of incubation, cells are trypsinizated and placed in Isotone solution and counted immediately using a Coulter particle-counter.

Animal Study: [5]

Animal Models Human breast carcinoma xenografts MCF-7 with human aromatase gene (MCF-7Ca)
Formulation 0.5% (w/v) solution of carboxymethylcellulos
Dosages 20 mg/kg/day
Administration orally administered by gavage once every 2 days
Solubility 0.5% CMC, , 10 mg/mL
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
1

References

[1] Haynes BP, et al. J Steroid Biochem Mol Biol, 2003, 87(1), 35-45.

[2] Bhatnagar AS, et al. J Steroid Biochem Mol Biol, 1990, 37(6), 1021-1027.

view more

Clinical Trial Information( data from http://clinicaltrials.gov)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02057133 Recruiting Breast Neoplasms Eli Lilly and Company 2014-03 Phase 1
NCT02109913 Recruiting Hormone Receptor Positive Malignant Neoplasm of Breast|Metastatic Breast Cancer VU University Medical Center|Borstkanker Onderzoek Groep|Novartis 2014-03
NCT02028507 Recruiting Metastatic Breast Cancer Spanish Breast Cancer Research Group|Pfizer 2014-03 Phase 3
NCT02115048 Not yet recruiting Breast Neoplasms Translational Research in Oncology|Boehringer Ingelheim 2014-04 Phase 2
NCT02093351 Not yet recruiting Solid Tumours AstraZeneca 2014-07 Phase 1

Chemical Information

Download Letrozole SDF
Molecular Weight (MW) 285.3
Formula

C17H11N5

CAS No. 112809-51-5
Storage 3 years -20℃Powder
6 months-80℃in DMSO
Synonyms CGS 20267
Solubility (25°C) * In vitro DMSO 57 mg/mL (199 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 0.5% CMC, 10 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Research Area

Customer Reviews (1)


Click to enlarge
Rating
Source Endocrinology. 2013 Jul;154(7):2296-307 . Letrozole purchased from Selleck
Method Immunohistochemistry
Cell Lines LNCaP tumor xenografts
Concentrations 10 mg/kg body weight
Incubation Time 2 d
Results Effect of aromatase inhibitor letrozole on cellular proliferation marker Ki-67 expression in LNCaP tumor xenografts. A, Ki-67 immunostaining in transverse sections of xenograft tumors from C, C+T, C+T+D, C+T+L, and C+T+D+L mice 2 days after testosterone replacement. Panel B, Quantification of Ki-67–positive cells in LNCaP tumors at day 2 post testosterone replacement. Error bars represent SEM. Number of animals in each group is shown in parentheses. ***, P <.0001.

Product Citations (3)

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Aromatase Products

  • PD123319

    PD 123319 is a potent, selective AT2 angiotensin II receptor antagonist with IC50 of 34 nM.

  • AZD3514

    AZD3514 is a potent and oral androgen receptor downregulator with Ki of 2.2 μM and has ability of reducing AR protein expression.

  • Anastrozole

    Anastrozole is a third-generation nonsteroidal selective aromatase inhibitor.

  • Exemestane

    Exemestane is an aromatase inhibitor, inhibits human placental and rat ovarian aromatase with IC50 of 30 nM and 40 nM, respectively.

    Features:17-hydroexemestane is the principal metabolite of Exemestane.

  • Aminoglutethimide

    Aminoglutethimide is an aromatase inhibitor with IC50 of 10 μM.

    Features:A first-generation aromatase inhibitor used for estrogen-dependent breast cancer.

  • Formestane

    Formestane is a second generation selective aromatase inhibitor with an IC50 of 80 nM.

  • Enzalutamide (MDV3100)

    Enzalutamide (MDV3100) is an androgen-receptor (AR) antagonist with IC50 of 36 nM.

  • Fulvestrant

    Fulvestrant is an estrogen receptor (ER) antagonist with IC50 of 0.94 nM.

  • Tamoxifen Citrate

    Tamoxifen Citrate is an antagonist of the estrogen receptor by competitive inhibition of estrogen binding.

Recently Viewed Items

Tags: buy Letrozole | Letrozole ic50 | Letrozole price | Letrozole cost | Letrozole solubility dmso | Letrozole purchase | Letrozole manufacturer | Letrozole research buy | Letrozole order | Letrozole mouse | Letrozole chemical structure | Letrozole mw | Letrozole molecular weight | Letrozole datasheet | Letrozole supplier | Letrozole in vitro | Letrozole cell line | Letrozole concentration | Letrozole nmr
Contact Us